异长春花碱联合丝裂霉素、顺铂治疗晚期非小细胞肺癌  

Combination of Vinorelbine,Mitomycin and Cisplatin in the Treatment of Advanced NSCLC

作　　者：缪彦[1] 张利华[1] 

机构地区：[1]高邮市人民医院肿瘤科,江苏高邮225600

出　　处：《河南肿瘤学杂志》2000年第5期335-336,共2页Henan Journal of Oncology

摘　　要：目的　评价异长春花碱、丝裂霉素和顺铂联合治疗晚期非小细胞肺癌的疗效。方法　 34例晚期非小细胞肺癌 19例为初治 ,15例为术后复发 ,均为初次化疗 ,用MNP方案 (异长春花碱 2 5mg/m2 静推 ,第 1天 ,丝裂霉素 8mg/m2 静推 ,第 1天 ,顺铂 30mg/m2静滴第 1～ 3天 ,每 3～ 4周重复疗程 )。结果　CR 2例 (5 9% )、PR 16例 (47% )总有效率为 5 2 9% ,中位生存期为 9 5月 ,1年生存率为 38 2 % ,毒副反应主要是骨髓抑制 ,无毒性相关死亡发生。结论　MNP方案是治疗晚期非小细胞肺癌疗效较高的方案 ,值得进一步研究。Objective To evalute the efficacy of combinatin of Vinorelbine,Mitomycin and Cisplatin (MNP) in the patients with advanced non-small cell lung cancer.Methods 34 cases of advanced non-small cell lung cancer had been studied in this clinical trial,nineteen patients of them had no prior chemotherapy for metastatic disease.Fifteen patients had relapse and metastasized non-small cell lung cancer of postoperation.The treatment with MNP:Vinorelbine 25 mg/m 2,I.V,day 1;Mitomycin 8 mg/m 2,I.V,day 1:Cisplatin 30 mg/m 2,I.V,drip,day 1～3.This treament repeated every 3～4 weeks.Results 2 patients (5.9%) achieved CR,16 patients (47%) achieved partial remision.Total response rate was 52.9%. The overall median survival time was 9.5 months.The one-year survival rate was 38.2%.Toxicities were mainly myelosuppression.The toxicity was moderate.Conclusion MNP regimen is regarded as a better regimen for advanced non-smell cell lung cancer and is worthy being further studied.

关 键 词：非小细胞肺癌 异长春花碱 丝裂霉素 顺铂 治疗 

分 类 号：R734.205[医药卫生—肿瘤]